Cargando…
Medication changes after switching from CONCERTA® brand methylphenidate HCl to a generic long-acting formulation: A retrospective database study
BACKGROUND: Observational studies of switching from branded to generic formulations of the same drug substance often lack appropriate comparators for the subjects who switched. Three generic formulations were deemed equivalent to Concerta: an authorized generic (AG) identical except for external pac...
Autores principales: | Fife, Daniel, Cepeda, M. Soledad, Baseman, Alan, Richards, Henry, Hu, Peter, Starr, H. Lynn, Sena, Anthony G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831385/ https://www.ncbi.nlm.nih.gov/pubmed/29489906 http://dx.doi.org/10.1371/journal.pone.0193453 |
Ejemplares similares
-
Bioequivalence of Sandoz methylphenidate osmotic-controlled release tablet with Concerta® (Janssen-Cilag)
por: Schapperer, Elisabeth, et al.
Publicado: (2015) -
Safety and efficacy of generic drugs with respect to brand formulation
por: Gallelli, Luca, et al.
Publicado: (2013) -
Evaluation of Physical Properties of Generic and Branded Travoprost Formulations
por: Wadhwani, Meenakshi, et al.
Publicado: (2016) -
Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study
por: Desai, Rishi J, et al.
Publicado: (2018) -
Cyclosporine: A Commentary on Brand versus Generic Formulation Exchange
por: Singh, A. K., et al.
Publicado: (2011)